Trial Site Detail
Drug: |
Crenolanib (CP-868,596) |
|||
|---|---|---|---|---|
Trial: |
Phase II Study of Crenolanib (CP-868,596), for the Treatment of Patients With Advanced Gastrointestinal Stromal Tumors With the D842-related Mutations and Deletions in the PDGFRA Gene |
|||
| Conditions: | Gastrointestinal Stromal Tumor | |||
Trial Status: |
Completed |
|||
Knight Cancer Institute at Oregon Health Sciences University (OHSU)3181 S.W. Sam Jackson Park Rd. |
Principal Investigator: |
Michael Heinrich, MD |
|---|---|
Contact: |
Tracy Walker, RN, BSN walkertr@ohsu.edu Contact: Hotline 503-494-1080 |
Activation Status of this Site: |
Closed |
Notes about this Site: |
|
Knight Cancer Institute at Oregon Health Sciences University (OHSU) Website: |
http://www.ohsu.edu/isr/trial_search1.cfm |
Navigating the Map
Use the plus (+) and minus (-) controls to zoom in/out.
Click and drag the map or use the arrows to move (pan) the map.
Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.